Tevogen Inc. (TVGN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TVGN SEC filings page.
This page shows Tevogen Inc. (TVGN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The filings show a development-stage business funded externally, with FY2025 spending split between R&D and administration while operating cash remained negative.
Across FY2024 and FY2025, operating cash flow stayed negative while financing cash flow remained positive and comparable in scale, showing that external funding—not operations—supported cash needs. Because revenue was not reported, the statements describe a cash-consuming development program whose economics are not yet visible through sales.
FY2025 R&D reached
FY2025 current ratio was 0.2x, indicating near-term obligations exceeded current assets. Total liabilities of
Financial Health Signals
Tevogen Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Tevogen Inc.'s EBITDA was -$5.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.7% from the same quarter a year earlier. Against the prior quarter it is down 4.9%.
Tevogen Inc. reported -$5.8M in net income in Q2 2026. This represents a decrease of 4.7% from the same quarter a year earlier. Against the prior quarter it is down 5.8%.
Tevogen Inc. earned -$1.52 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 5.6%.
Not reported for Q2 2026.
Cash & Balance Sheet
Tevogen Inc. held $1.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Tevogen Inc. invested $3.3M in research and development in Q2 2026. This represents an increase of 21.6% from the same quarter a year earlier. Against the prior quarter it is up 4.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
TVGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.3M+21.6% | $3.1M-1.9% | N/A | $3.1M-4.6% | $2.7M-34.5% | $3.2M | N/A | $3.3M+192.0% |
| SG&A Expenses | $2.4M-13.3% | $2.3M-68.4% | N/A | $2.6M-7.3% | $2.7M-38.7% | $7.2M-17.7% | N/A | $2.8M+133.8% |
| Operating Income | -$5.7M-4.0% | -$5.4M+47.8% | N/A | -$5.7M+5.9% | -$5.4M+36.7% | -$10.4M | N/A | -$6.1M-161.7% |
| EBITDA | -$5.6M-8.7% | -$5.3M+47.9% | N/A | -$5.7M+4.7% | -$5.2M+39.4% | -$10.3M | N/A | -$6.0M-168.2% |
| Interest Expense | -$98K-158.7% | -$71K-389.6% | N/A | -$62K-600.4% | -$38K-633983.3% | $25K-84.2% | N/A | $12K-95.8% |
| Net Income | -$5.8M-4.7% | -$5.4M+47.5% | N/A | -$5.7M+2.7% | -$5.5M+43.0% | -$10.4M-192.0% | N/A | -$5.9M-50.7% |
| EPS (Basic) | -$1.52+11.1% | -$1.61+50.5% | -$7.96-13166.7% | -$0.030.0% | -$1.71-4175.0% | -$3.25-4162.5% | -$0.06+57.1% | -$0.030.0% |
| EPS (Diluted) | -$1.52 | -$1.61 | -$7.96 | -$0.030.0% | -$1.71 | -$3.25-1150.0% | -$0.06+57.1% | -$0.03 |
| Diluted Shares (Avg) | 4M | 3M | N/A | 196M+15.2% | 3M | 3M-97.7% | N/A | 170M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
TVGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.7M+10.7% | $4.9M+20.8% | $4.4M+26.6% | $4.5M+4.8% | $4.3M+29.0% | $4.1M+21.1% | $3.5M-37.1% | $4.3M-83.8% |
| Current Assets | $2.0M-2.5% | $2.1M-30.4% | $1.5M-34.8% | $2.1M-39.9% | $2.1M-15.8% | $3.1M+28.2% | $2.4M+37.0% | $3.5M+783.1% |
| Cash & Equivalents | $1.1M+57.9% | $692K-64.9% | $0 | $1.0M-55.5% | $685K-39.6% | $2.0M+49.9% | $0 | $2.3M-90.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $13.6M-1.0% | $14.8M+25.2% | $12.6M+24.5% | $12.3M+17.5% | $13.8M+25.7% | $11.8M+28.7% | $10.1M-89.9% | $10.5M-91.1% |
| Current Liabilities | $6.2M-23.9% | $7.3M-16.6% | $7.1M-21.8% | $6.7M-35.3% | $8.1M-23.8% | $8.7M-2.4% | $9.0M-89.4% | $10.4M+470.2% |
| Non-Current Liabilities | $7.5M+31.6% | $7.5M+143.9% | $5.5M+407.7% | $5.6M+8591.6% | $5.7M+1607.3% | $3.1M+1249.4% | $1.1M-92.4% | $64K-99.9% |
| Total Equity | -$8.9M+6.3% | -$9.8M-27.5% | -$8.2M-23.4% | -$7.8M-26.4% | -$9.5M-23.8% | -$7.7M-33.0% | -$6.7M+92.9% | -$6.2M+93.2% |
| Retained Earnings | -$150.9M-16.7% | -$145.1M-17.3% | -$139.7M-23.2% | -$135.0M-29.9% | -$129.3M-31.8% | -$123.8M-40.0% | -$113.4M-13.8% | -$103.9M-543.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TVGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.0M+5.8% | -$2.7M+17.4% | -$2.2M+28.4% | -$3.6M+4.1% | -$3.2M-6.9% | -$3.3M-52.9% | -$3.0M-54.2% | -$3.8M-111.4% |
| Depreciation & Amortization | $60K-79.3% | $59K-44.0% | $86K-17.2% | $27K-73.2% | $291K+190.8% | $105K+7.2% | $104K+2.7% | $102K+8.7% |
| Stock-Based Compensation | N/A | $2.8M-60.9% | N/A | $3.2M-2.5% | $3.2M-21.8% | $7.3M-72.3% | N/A | $3.3M |
| Financing Cash Flow | $3.4M+78.7% | $2.9M-28.2% | $1.8M-12.0% | $4.0M-20.0% | $1.9M-32.1% | $4.0M+64.7% | $2.0M+373.7% | $5.0M+426.3% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TVGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$8.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Tevogen Inc. TVGN | FY2025 | N/A | N/A | N/A | $46.3M | — |
| Kyverna Therapeutics, Inc. KYTX | FY2025 | N/A | -$161.3M | N/A | $384.0M | — |
| Innate Pharma S.A. IPHA | FY2025 | $50.0M | N/A | N/A | $165.3M | — |
| NeOnc Technologies Holdings, Inc. NTHI | FY2025 | $40K | N/A | N/A | $78.6M | — |
| Caribou Biosciences, Inc. CRBU | FY2025 | $11.2M | -$148.1M | N/A | $53.3M | 52/100 |
| Ventyx Biosciences, Inc. VTYX | FY2024 | N/A | -$135.1M | N/A | $1.0B | — |
Where Tevogen Inc. Ranks
Frequently Asked Questions
What is Tevogen Inc.'s free cash flow?
Tevogen Inc. (TVGN) recorded an outflow of $12.4M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Tevogen Inc.'s operating cash flow?
Tevogen Inc. (TVGN) recorded an outflow of $12.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Tevogen Inc.'s total assets?
Tevogen Inc. (TVGN) had $4.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Tevogen Inc.'s capital expenditures?
Tevogen Inc. (TVGN) invested $64K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Tevogen Inc. spend on research and development?
Tevogen Inc. (TVGN) invested $11.1M in research and development during fiscal year 2025.
What is Tevogen Inc.'s current ratio?
Tevogen Inc. (TVGN) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Tevogen Inc.'s P/E ratio?
Tevogen Inc. (TVGN) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $46.3M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Tevogen Inc.'s price-to-sales ratio?
Tevogen Inc. (TVGN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $46.3M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Tevogen Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Tevogen Inc. (TVGN) held $0 in cash, cash equivalents and investments, and reported an operating cash outflow of $12.3M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Tevogen Inc.'s debt-to-equity ratio negative or not reported?
Tevogen Inc. (TVGN) has negative shareholder equity of -$8.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.